Insmed (INSM)
(Delayed Data from NSDQ)
$67.99 USD
+3.28 (5.07%)
Updated Jun 21, 2024 04:00 PM ET
After-Market: $67.95 -0.04 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Income Statements
Fiscal Year end for Insmed, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 305 | 245 | 188 | 164 | 136 |
Cost Of Goods | 66 | 55 | 44 | 40 | 24 |
Gross Profit | 240 | 190 | 144 | 125 | 112 |
Selling & Adminstrative & Depr. & Amort Expenses | 949 | 648 | 519 | 390 | 348 |
Income After Depreciation & Amortization | -710 | -457 | -375 | -265 | -235 |
Non-Operating Income | 44 | 4 | -21 | 2 | 9 |
Interest Expense | 82 | 26 | 40 | 30 | 28 |
Pretax Income | -747 | -480 | -436 | -293 | -254 |
Income Taxes | 3 | 1 | -2 | 1 | 1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -750 | -482 | -435 | -294 | -254 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -750 | -482 | -435 | -294 | -254 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -689 | -441 | -329 | -230 | -205 |
Depreciation & Amortization (Cash Flow) | 21 | 16 | 46 | 36 | 30 |
Income After Depreciation & Amortization | -710 | -457 | -375 | -265 | -235 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 140.43 | 123.04 | 112.11 | 97.61 | 84.56 |
Diluted EPS Before Non-Recurring Items | -5.34 | -3.90 | -3.75 | -3.01 | -3.01 |
Diluted Net EPS (GAAP) | -5.34 | -3.91 | -3.88 | -3.01 | -3.01 |
Fiscal Year end for Insmed, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 75.50 | 83.69 | 79.07 | 77.23 | 65.21 |
Cost Of Goods | 17.46 | 18.44 | 16.71 | 16.59 | 13.83 |
Gross Profit | 58.04 | 65.25 | 62.37 | 60.63 | 51.38 |
SG&A, R&D, and Dept/Amort Expenses | 203.54 | 243.52 | 210.03 | 296.16 | 199.54 |
Income After SG&A, R&D, and Dept/Amort Expenses | -145.50 | -178.27 | -147.66 | -235.53 | -148.16 |
Non-Operating Income | 10.05 | 13.99 | 9.57 | 11.87 | 8.88 |
Interest Expense | 21.04 | 20.78 | 20.29 | 20.62 | 20.00 |
Pretax Income | -156.50 | -185.06 | -158.39 | -244.28 | -159.28 |
Income Taxes | 0.59 | 1.00 | 0.54 | 0.53 | 0.48 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -157.09 | -186.06 | -158.93 | -244.81 | -159.76 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -157.09 | -186.06 | -158.93 | -244.81 | -159.76 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 148.46 | 144.81 | 142.90 | 137.55 | 136.36 |
Diluted EPS Before Non-Recurring Items | -1.06 | -1.28 | -1.10 | -1.78 | -1.17 |
Diluted Net EPS (GAAP) | -1.06 | -1.28 | -1.11 | -1.78 | -1.17 |